CAT-1 Inhibitors
Chemicals classified as CAT-1 inhibitors encompass a wide range of compounds with diverse mechanisms of action. They primarily exert their effects by indirectly modulating CAT-1 activity. While there are no known direct inhibitors of CAT-1, several compounds can indirectly inhibit this transporter by influencing related cellular processes or signaling pathways. One of the key mechanisms through which these compounds act is through modulation of intracellular calcium levels. CAT-1 activity is known to be regulated by calcium, and several of the identified inhibitors, such as 2-Aminoethyl diphenylborinate (2-APB), Nifedipine, Verapamil, Dantrolene, Thapsigargin, and Cyclosporin A, exert their effects by influencing calcium homeostasis. These compounds inhibit various receptors and channels involved in calcium signaling, leading to changes in intracellular calcium levels that can influence CAT-1 activity.
Another key mechanism of action is through inhibition of the PI3K/Akt/mTOR pathway, as demonstrated by Rapamycin, LY294002, and Wortmannin. CAT-1 is downstream ofthe mTOR pathway, and inhibition of this pathway can lead to reduced CAT-1 activity. The PI3K/Akt/mTOR pathway is a central signaling hub for numerous cellular processes, including cell growth and proliferation, and its activity can have broad effects on cellular physiology, including modulation of transporter activity. Additionally, Nitric Oxide Synthase (NOS) inhibitors like L-NAME and L-NMMA act by reducing the production of nitric oxide (NO), a known regulator of CAT-1. In this way, these inhibitors can indirectly influence CAT-1 activity. Finally, L-Arginine is a unique case, where it serves as a substrate for CAT-1 but at high concentrations, it can act as a competitive inhibitor. By saturating CAT-1 with L-Arginine, other amino acids are unable to access the transporter, thereby reducing CAT-1's overall activity. In summary, while there are no known direct inhibitors of CAT-1, a range of compounds can indirectly influence this transporter's activity. These compounds act through a variety of mechanisms, including modulation of calcium signaling pathways, inhibition of the PI3K/Akt/mTOR pathway, and regulation of nitric oxide production. These mechanisms provide multiple potential points of intervention for modulating CAT-1 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
L-Arginine is a substrate of CAT-1, but at high concentrations, it can competitively inhibit the transporter. By saturating CAT-1 with L-Arginine, other amino acids are denied access to the transporter, reducing CAT-1's overall activity. | ||||||
L-NG-Nitroarginine Methyl Ester (L-NAME) | 51298-62-5 | sc-200333 sc-200333A sc-200333B | 1 g 5 g 25 g | $48.00 $107.00 $328.00 | 45 | |
L-NAME is a nitric oxide synthase (NOS) inhibitor that indirectly affects CAT-1. By inhibiting NOS, the downstream production of nitric oxide (NO) is reduced. NO is known to regulate CAT-1 activity, so the reduction of NO production by L-NAME can lead to decreased CAT-1 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that indirectly affects CAT-1. CAT-1 is downstream of the mTOR pathway, and inhibiting mTOR with Rapamycin reduces the pathway's activity, which can result in decreased CAT-1 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, a key enzyme in the PI3K/Akt/mTOR pathway. By inhibiting PI3K, LY294002 can reduce the activity of this pathway and indirectly inhibit CAT-1, which is downstream of mTOR. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K. Similar to LY294002, Wortmannin can decrease the activity of the PI3K/Akt/mTOR pathway and thereby indirectly inhibit CAT-1. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
2-APB is an inhibitor of IP3 receptors, which are involved in calcium signaling. CAT-1 activity is known to be regulated by intracellular calcium levels, so by inhibiting IP3 receptors and reducing calcium release, 2-APB can indirectly inhibit CAT-1. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is an L-type calcium channel blocker. By preventing calcium influx through these channels, Nifedipine can reduce intracellular calcium levels and indirectly inhibit CAT-1, whose activity is regulated by calcium. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $374.00 | ||
Verapamil is another L-type calcium channel blocker. Similar to Nifedipine, Verapamil can reduce intracellular calcium levels and indirectly inhibit CAT-1. | ||||||
L-NG-Monomethylarginine, Acetate Salt (L-NMMA) | 53308-83-1 | sc-200739 sc-200739A sc-200739B sc-200739C | 25 mg 100 mg 1 g 100 g | $90.00 $260.00 $800.00 $40378.00 | 3 | |
L-NMMA is a nitric oxide synthase inhibitor. By reducing NO production, L-NMMA can indirectly inhibit CAT-1, whose activity is regulated by NO. | ||||||
Dantrolene | 7261-97-4 | sc-500165 | 25 mg | $350.00 | 7 | |
Dantrolene inhibits ryanodine receptors, reducing calcium release from the sarcoplasmic reticulum. This can lead to lower intracellular calcium levels, indirectly inhibiting CAT-1. | ||||||